Enabling Projects

In vivo human therapeutic cell tracking using a [19F]-perfluorocarbon cellular MRI contrast agent: Phase I feasibility and preliminary safety trial

 

Dr. Gregory Dekaban, Robarts Research, McMaster University
Approved January 17, 2017 | Project value $89,014 | 3 partners | $43,500 from BioCanRx

 

Eligible cancers: all cancers that use virus antigens
Keywords: antigen presenting cells, Cell-based cancer vaccine immunotherapy

 

 
 

 
 

Oncolytic vaccinia virus for bladder cancer treatment: preparation for a phase I/II trial

 

Dr. David Evans, University of Alberta
Approved January 17, 2017 | Project value $452,108 | 2 partners | $226,054 from BioCanRx

 

Eligible cancers: bladder cancer (non-muscle invasive bladder cancer)
Keywords: oncolytic vaccinia virus

 

 
 

 
 

Capacity building for Chimeric Antigen Receptor (CAR)-modified T cell therapies in Canada

 

Dr. Rob Holt, BC Cancer Agency, University of British Colombia
Approved January 17, 2017 | Project value $4,489,250 | 2 partners | $1,244,375 from BioCanRx

 

Eligible cancers: blood cancers
Keywords: CAR-T cells, CD19

 

 
 

 
 

Garbage to Gold: expansion of Therapeutic Regulatory T Cells from discarded thymus

 

Dr. Megan Levings, BC Children’s Hospital Research Institute
Approved January 17, 2017 | Project value $847,085 | 5 partners | $275,659 from BioCanRx

 

Eligible cancers: hematologic malignancies
Keywords: regulatory T cell (Treg), graph-versus host disease

 

 
 

 
 

Adoptive T cell therapy targeting patient-specific driver mutations in lymphoma

 

Dr. Brad Nelson, BC Cancer Agency, University of British Colombia
Approved October 14, 2016 | Project value $718,547 | 3 partners | $358,186 from BioCanRx

 

Eligible cancers: follicular lymphoma
Keywords: adoptive cell therapy, T cells, autologous peripheral blood mononuclear cells, CD8+

 

 
 

 
 

Development of predictive companion biomarkers and therapeutic monitoring for hypermutant cancers to immune checkpoint inhibition

 

Dr. Uri Tabori, The Hospital for Sick Children, University of Toronto
Approved October 14, 2016 | Project value $1,490,253 | 1 partners | $744,996 from BioCanRx

 

Eligible cancers: hyper-mutant cancers
Keywords: biomarkers, PD-1 blokade

 

 
 

 
 

COMBINING ONCOLYTIC VACCINE THERAPY WITH ADOPTIVE CELL THERAPY TO TARGET CANCERS EXPRESSING MAGE-A3

 

Dr. Yonhong Wan, McMaster University
Approved June 10, 2015 | Project value $326,885 | 2 partners | $186,885 from BioCanRx

 

Eligible cancers: anal, bladder, breast, cervical, colon, esophageal, kidney, liver, lung, melanoma, mouth, ovarian, pancreatic, prostate, stomach, uterine
Keywords: oncolytic virus, oncolytic vaccine, adoptive cell therapy, autologous T cells, adenovirus vaccine, Maraba oncolytic virus, AdMA3, MG1MA3, MAGE-A3 antigen

 

 
 

 
 

ADVANCED PRECLINICAL DEVELOPMENT OF THE ONCOLYTIC VACCINE PLATFORM TO PREPARE REQUIREMENTS FOR A CLINICAL TRIAL OF PATIENTS WITH HPV-ASSOCIATED CANCERS

 

Dr. Brian Lichty, McMaster University
Approved June 10, 2015 | Project value $1.16 million | 4 partners | $582,264 from BioCanRx

 

Eligible cancers: anal, cervical, esophageal, larynx, oral
Keywords: oncolytic virus, oncolytic vaccine, adenovirus vaccine, Maraba oncolytic virus, HPV, human papilloma virus, AdHPV, MG1HPV, HPV-E6/E7 antigen

 

 
 

 
 

DEVELOPMENT OF IMMUNE REGULATING ANTIBODIES FOR USE IN COMPANION ANIMAL CLINICAL TRIALS

 

Dr. Jason Moffat, University of Toronto
Approved June 10, 2015 | Project value $288,252 | 1 partner | $143,716 from BioCanRx

 

Eligible cancers: melanoma
Keywords: synthetic antibodies, immune checkpoint inhibitors

 

 
 

 
 

DEVELOPMENT OF ANTIBODY-BASED PLATFORMS THAT SPECIFICALLY TARGET CANCER CELLS

 

Dr. Steven Jones, BC Cancer Agency, University of British Columbia, Simon Fraser University
Approved September 29, 2015 | Project value $2.2M | 1 partner | $749,000 from BioCanRx

 

Eligible cancers: to be determined by study
Keywords: antibodies, antibody-drug conjugates, ADCs, theranostics, radioimmunotherapy, radio-immuno conjugate, diagnostic imaging, pancratistatin ADCs

 

 
 

 
 

DEVELOPING T CELLS THAT TARGET ANTIGENS SPECIFIC TO LYMPHOID CANCERS

 

Dr. Denis Claude Roy, Hôpital Maisonneuve-Rosemont, Université de Montréal
Dr. Claude Perreault, Hôpital Maisonneuve-Rosemont, Université de Montréal
Approved September 29, 2015 | Project value $635,275 | 3 partners | $279,875 from BioCanRx

 

Eligible cancers: chronic lymphocytic leukemia (CLL), lymphoid hematologic malignancies, non-Hodgkin’s lymphoma,
Keywords: adoptive cell therapy, minor histocompatibility antigens, MiHAs